Investigating RNA modifications and treatment response in multiple myeloma
RNA m6A modifications and treatment response in multiple myeloma
['FUNDING_R21'] · UNIVERSITY OF CHICAGO · NIH-11064787
This study is looking at how a special change in RNA, called m6A, might influence how well patients with multiple myeloma respond to treatment, with the goal of finding better ways to personalize care for those who struggle with their therapy.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11064787 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how specific RNA modifications, particularly N6-methyladenosine (m6A), affect the treatment response in patients with multiple myeloma, a type of blood cancer. The study aims to develop new quantitative methods to analyze these RNA modifications at a high resolution, which could help identify why some patients experience poor outcomes despite receiving modern therapies. By examining the role of m6A in disease progression and treatment resistance, the research seeks to uncover new prognostic factors that could guide personalized treatment strategies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those who have experienced treatment resistance or relapse.
Not a fit: Patients with multiple myeloma who are in complete remission or have not yet received treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better prognostic tools for patients with multiple myeloma.
How similar studies have performed: While the role of RNA modifications in cancer is an emerging field, this specific approach to studying m6A in multiple myeloma is relatively novel and has not been extensively tested.
Where this research is happening
CHICAGO, UNITED STATES
- UNIVERSITY OF CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHIU, BRIAN C-H — UNIVERSITY OF CHICAGO
- Study coordinator: CHIU, BRIAN C-H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers